Pitch & Match
Through Pitch & Match, we provide our investors and presenting companies the opportunity to know each other before event day, get engaged through presentation, Q&A and arrange immediate follow-up meetings.
Presentation fees: €3000 （Includes presentation fee and one registration for presenter）
Presentation Companies Can:
- Meet pre-vetted decision-makers from top Chinese pharma and investment firms
- Know your audience prior to the pitch
- Maximized your company visibility through pre-conference promotion
- Present for 8min with Powerpoint slides
- Schedule immediate follow-up meetings through on-target partnering
Who Should Apply
• Biotech
• Drug development
• Platform technology
• Medical device
• Digital health
Opportunities our audience are seeking
• Licensing
• Co-Development
• M&A
• Joint Venture
• And more…
Hengrui Pharmaceuticals
Description: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.
Recent Deal: Mycovia and Hengrui Medicine have signed an agreement to develop and commercialise the former’s investigational drug, VT-1161 for RVVC
Interests: oncology, autoimmune, metabolic and CV
Recent Deal: Verastem grants CSPC exclusive rights to develop and commercialize the cancer drug Copiktra duvelisib in China.
Interests: Oncology, CV, Autoimmune
Fosun Pharma
Description: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform.
Recent Deal: Revance Therapeutics grants Fosun exclusive Chinese rights to RT002.
Interests: oncology, cardiovascular disease, CNS, liver disease, medical device
Salubris Biotherapeutics
Description: Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution.
Recent Deal: Viracta Therapeutics Inc. granted Salubris exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the great China.
Interests: Oncology, CV and metabolic diseases
Luye Pharma
Description: Luye Pharma is an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.
Recent Deal: Luye Pharma and PharmaMar Sign Licensing Agreement for the Development and Commercialization of Zepsyre® in China.
Interests: Oncology, CNS, CV, diabetes, digestive disease and metabolic diseases
Huadong Medicine
Description: A fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines, with annual revenue of 4.5 billion USD.
Recent Deal: Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets
Interests: Diabetes, Aesthetics, autoimmune disease, digestive disease, CV, oncology, and infectious disease.
TESTIMONIAL
The Pitch and Match session at China Focus generated a high level of interest from investors and was a way to quickly connect with a relevant and sizeable audience. We are in due diligence with two companies as a result.
I wanted express my appreciation for the opportunity to participate in ‘China Focus @BWB’. The event was organized great, the cross section of companies both domestic US and China based companies made the conference a worthwhile event. I would also add that the level of decision maker attending was fantastic there where many CEOs, Managing Directors, and Founders all in attendance; which are essential element when have partnering discussions. The Key addresses by the two professors were quite insightful. I hope be able to participate in future events that MyBioGate will sponsor!
I was really glad I had a chance to attend China Focus@BWB at Boston in 2019. It provided great opportunity to meet entrepreneurs, investors and make new friends. It is honored to present my startup company (RNP Therapeutics) in front of investors, who later on might be interested in further discussion. One-on-one meeting is extremely useful to make connection. I hope I can attend next meeting in future.